Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | PKM | P14618 | 4/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9280850 | 1.00 | KMT2A (0.58) | KMT2AMEN1HRH3ALDH1A1PKM | |
| SCHEMBL9280010 | 0.85 | ALDH1A1 (0.65) | KMT2AMEN1ALDH1A1PKMCYP3A4 | |
| SCHEMBL9280014 | 0.85 | ALDH1A1 (0.65) | KMT2AMEN1ALDH1A1PKMCYP3A4 | |
| SCHEMBL9275791 | 0.84 | F2 (0.71) | KMT2AMEN1ALDH1A1PKMCYP3A4 | |
| SCHEMBL9275807 | 0.84 | F2 (0.71) | KMT2AMEN1ALDH1A1PKMCYP3A4 | |
| SCHEMBL17048543 | 0.79 | F2 (0.58) | KMT2AMEN1ALDH1A1PKMCYP3A4 | |
| SCHEMBL9277848 | 0.79 | ALDH1A1 (0.63) | KMT2AMEN1ALDH1A1CYP2C19LMNA | |
| SCHEMBL9277842 | 0.79 | ALDH1A1 (0.63) | KMT2AMEN1ALDH1A1CYP2C19LMNA | |
| SCHEMBL9277032 | 0.79 | HRH3 (0.53) | HRH3ALDH1A1PKMCYP3A4CYP2C9 | |
| SCHEMBL9277038 | 0.79 | HRH3 (0.53) | HRH3ALDH1A1PKMCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9193762-B2 | Selective inhibitors of prolylcarboxypeptidase | UNIVERSITY OF MISSISSIPPI (US) | 2015-11-24 | — | — | US | disclosed |
| US-20130310311-A1 | NOVEL SELECTIVE INHIBITORS OF PROLYLCARBOXYPEPTIDASE | THE UNIVERSITY OF MISSISSIPPI | 2013-11-21 | — | — | US | disclosed |
| WO-2012075287-A2 | NOVEL SELECTIVE INHIBITORS OF PROLYLCARBOXYPEPTIDASE | THE UNIVERSITY OF MISSISSIPPI (US) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310311-A1 | NOVEL SELECTIVE INHIBITORS OF PROLYLCARBOXYPEPTIDASE | PREP, PEPD, DPEP1 | KMT2A 3406/4885MEN1 2681/4885HRH3 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.